1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

$Thumbnail for A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)$

ABCL - 484

A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Kim Saverno

Poster Presenter: Kim Saverno

Video

Thumbnail for Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

ABCL - 489

Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

Jason Westin

Poster Presenter: Jason Westin

SOHO 2026 Annual Meeting

Posters by Session

A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

HIV-Associated Plasmablastic Lymphoma Presenting With Spontaneous Tumor Lysis Syndrome and Hypercalcemia of Malignancy

Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: A Systematic Review

Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin (Mosun-Pola) Shows a Sustained Progression-Free Survival Benefit Compared With Rituximab Plus Polatuzumab Vedotin (R-Pola) in Patients With Relapsed or Refractory Large B-Cell Lymphoma After Long-Term Follow-Up

Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma

Navigating the WHO-HEAM5 Lymphoma Landscape: An Imaging Primer for Hematologists

EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)